Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Alnylam Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -1.4500 | -2.715 | 47 | 81 | -89 | -439 | -92 | -478 | -92 | -498 | 27 | 52 |
| 2015 | -4.8500 | -3.336 | 50 | 43 | -360 | -271 | 36 | -253 | -184 | -276 | 44 | 45 |
| 2016 | -3.4500 | -4.879 | 41 | 42 | -290 | -402 | -296 | -387 | -296 | -416 | 60 | 44 |
| 2017 | -4.7900 | -5.286 | 47 | 70 | -410 | -463 | -424 | -450 | -424 | -471 | 89 | 74 |
| 2018 | -5.4200 | -7.650 | 89 | 70 | -490 | -735 | -500 | -729 | -500 | -789 | 199 | 74 |
| 2019 | -7.5700 | -7.899 | 74 | 222 | -761 | -878 | -835 | -822 | -814 | -929 | 382 | 234 |
| 2020 | -8.1100 | -7.203 | 219 | 475 | -886 | -777 | -939 | -659 | -939 | -772 | 479 | 502 |
| 2021 | -7.4600 | -6.444 | 492 | 820 | -858 | -723 | -771 | -724 | -828 | -608 | 588 | 527 |
| 2022 | -7.2000 | -8.953 | 844 | 1,013 | -852 | -770 | -709 | -775 | -708 | -565 | 620 | 513 |
| 2023 | -9.3000 | -3.478 | 1,037 | 1,826 | -1,131 | -440 | -894 | -852 | -785 | -621 | 770 | 564 |
| 2024 | -3.5200 | -1.976 | 1,828 | 2,231 | -440 | -246 | -228 | -1,708 | -282 | -1,765 | 795 | 2,359 |
| 2025 | - | -1.083 | - | 2,628 | - | -193 | - | -2,011 | - | -2,079 | - | 2,779 |
| 2026 | - | 2.960 | - | 3,534 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 6.903 | - | 4,492 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 12.354 | - | 5,750 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Equal-Weight
Prev. Grade
Equal-Weight
Nov. 6, 2024
Equal-Weight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
Underweight
Prev. Grade
Underweight
Nov. 6, 2024
Underweight
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-25.240% $61.81 · MISS
Nov. 6, 2024Price Then
$265.29
Price Target
$306.70
Price Now
$244.89